Smicheliolide-cinnamic acid derivative as well as preparation method and application thereof

By splicing the molecular splicing of smelactone and cinnamic acid units, the smelactone-cinnamic acid derivatives are synthesized, which solves the existing smelactone problems of poor water solubility and low bioavailability, significantly improves anti-tumor activity and provides high efficiency anti-tumor drug solutions.

CN119019353APending Publication Date: 2024-11-26ACCENDATECH (TIANJIN) BIOPHARMACEUTICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411115044.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing natural products of lactones exhibit pharmacological activity in the field of anti-tumor, but due to poor water solubility and low bioavailability, further application of their drug development is limited.

Method used

By optimizing the structural structure of the lactone and splicing it with the cinnamic acid unit molecules, a series of lactone-cinnamic acid derivatives are synthesized to improve their anti-tumor performance and form highly active potential pharmaceutical molecules.

Benefits of technology

It significantly improves anti-tumor activity, provides potential new anti-tumor drugs, and through the introduction of different substituent groups, the in vitro inhibition rate and IC50 value of the drug are optimized, enhancing the clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019353A_ABST
    Figure CN119019353A_ABST
Patent Text Reader

Abstract

The invention discloses sphaelactone-cinnamic acid derivatives as well as a preparation method and application thereof, two sphaelactone hydroxyl derivatives are respectively subjected to molecular splicing with cinnamic acid units with different structures to synthesize a series of sphaelactone-cinnamic acid derivatives with structures shown as a formula I # imgabs0 # and a formula II # imgabs1 #, and the sphaelactone-cinnamic acid derivatives are applied to preparation of tumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a Michelia lactone-cinnamic acid derivative and a preparation method and application thereof. Background Art

[0002] The sesquiterpene lactone natural product michelinolactone (MCL) has a wide range of pharmacological activities, such as anti-tumor, anti-inflammatory, immunomodulatory, neuroprotective, and organ protective effects, and is particularly outstanding in the anti-tumor field. Although relevant scholars have modified it to varying degrees based on its structure, it still has defects such as poor water solubility and low bioavailability, which limits its further drug development.

[0003] Cinnamic acid, also known as cinnamic acid, is an unsaturated aromatic acid that can be isolated from cinnamon bark or benzoin. Synthetic cinnamic acid has been widely used in many fields such as flavors and fragrances, food additives, pharmaceutical chemicals, and organic synthesis. Cinnamic acid and its derivatives have a very wide range of anti-solid tumor activity, including melanoma, leukemia, liver cancer, cervical cancer, etc. The biological activity of different cinnamic acid derivatives is attributed to the nature and position of the substituent functional groups. At present, there is a lack of therapeutic therapies with drug resistance and low adverse side effects to control tumor cell growth, so it is necessary to explore the development of drugs with better therapeutic effects based on cinnamic acid. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a Michelia lactone-cinnamic acid derivative and a composition, a preparation method and an application thereof.

[0005] The technical solution adopted in the present application is: a Michelia lactone-cinnamic acid derivative, whose general structural formula is shown in Formula I and Formula II according to the different allylic oxidation sites of Michelia lactone:

[0006]

[0007] Among them, formula I is prepared from 9R-hydroxy Michelia lactone, and formula II is prepared from 9R-hydroxy Michelia lactone.

[0008] Preferably, according to the different structures of cinnamic acid, R is represented differently, and R is one of the following structures: R = H, R = 4-Br, R = 2-OCH3, R = 4-OCH3, R = 2-CH3, R = 2-OCF3, R = 3-F, R = 4-OH, R = 4-F, R = 2-OCH2CH3, R = 4-CF3, R = 4-Cl, R = 2-OCOCH3, R = 3-OCN3, R = 3-C l. R=4-isopropyl、R=4-OCH2CH3、R=4-CN、R=3,5-OCH3、R=2,5-OCH3、R=2,3-OCH3、R=3,4-OC H3, R=2,3,4-OCH3, R=3,4,5-OCH3, R=2,3,4-OCH3, R=3,4-dihydrofuran, R=3,4-pyridine.

[0009] Preferably, the formula I is preferably

[0010] The formula II is preferably

[0011] A pharmaceutical composition comprising the Michelia lactone-cinnamic acid derivative according to claim 1 and a pharmaceutically acceptable pharmaceutical carrier, excipient or other tumor treating drug.

[0012] Preferably, the pharmaceutical carrier or excipient is one or more solid, semisolid, liquid preparations and pharmaceutical product adjuvants, and the pharmaceutical composition is administered in two forms: injection or oral administration. The injection is through intravenous injection or intramuscular injection, and the oral dosage form is tablets or capsules.

[0013] Preferably, the combination medicine is used in medicines for treating various cancers.

[0014] Preferably, the synthesis route of the Michelia lactone-cinnamic acid derivative is as follows:

[0015] S1. Obtaining hydroxylated derivatives of Michelia lactone 9R-hydroxy Michelia lactone and 2R-hydroxy Michelia lactone by Riley oxidation;

[0016] S2. The two hydroxy derivatives of Michelia lactone prepared in step S1 are molecularly spliced ​​with cinnamic acid units with different structures to synthesize a series of Michelia lactone-cinnamic acid derivatives (3-a) to (27-a) and (3-b) to (27-b).

[0017] Preferably, the step S1 specifically includes the following steps:

[0018] S11, at room temperature, add MCL into a dry three-necked round-bottom flask, then add dry DCM and dissolve it, then add SeO2 and t-BuOOH dried over anhydrous sodium sulfate, stir the mixture at room temperature for 6 hours, and set aside;

[0019] S12. After most of the substrates are converted completely by TLC, a saturated Na2S2O3 solution is added to quench the reaction until a brick-red amorphous selenium precipitate appears in the reaction solution. The reaction solution is then filtered through diatomaceous earth and extracted with DCM. After the extraction is completed, the crude product is washed, dried, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product is purified by a silica gel column for later use.

[0020] S13, adding the crude product purified in step S12 into a round-bottom flask, then adding dried DCM to dissolve it, then slowly adding dried Et3N to react, stirring the reaction solution for 15 minutes, adding TESCl, stirring the mixture reaction solution overnight, and adding H2O to quench the reaction after monitoring the complete conversion of the substrate by TLC, then extracting, washing, drying, filtering and concentrating under reduced pressure, and then purifying by silica gel column to obtain colorless oily compound 1-a and light yellow oily compound 1-b respectively;

[0021] S14, dissolving the compound 1-a obtained in step S13 in a mixed solution of THF and TBAF, and stirring at room temperature overnight. After the TLC monitoring substrate is basically converted, H2O is added to quench the reaction, extracted with EtOAc, washed, dried, filtered, concentrated under reduced pressure, and purified with a silica gel column to obtain a yellow solid compound 2-a; dissolving the compound 1-b obtained in step S13 in a mixed solution of THF and TBAF, and stirring at room temperature overnight. After the TLC monitoring substrate is basically converted, H2O is added to quench the reaction, extracted with EtOAc, washed, dried, filtered, concentrated under reduced pressure, and purified with a silica gel column to obtain a yellow solid compound 2-a.

[0022] Preferably, the step S2 specifically includes the following steps:

[0023] At 0°C, compound 2-a prepared in step S14 is added to a round-bottom flask, DCM is added to dissolve it, and then Et3N and DMAP are added until the pH value of the solution is 9-10, and then cinnamic acid and EDCI are added, and the mixture is stirred overnight. After the substrate is basically converted as monitored by TLC, a saturated NaHCO3 solution is added to quench the reaction, and then extracted with DCM, washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered and concentrated under reduced pressure. It is then purified by silica gel chromatography to obtain the corresponding (3-a) to (27-a) cinnamic acid derivatives according to the different structures of the added cinnamic acid;

[0024] At 0°C, compound 2-b prepared in step S14 is added to a round-bottom flask, DCM is added to dissolve it, and then Et3N and DMAP are added until the pH value of the solution is 9-10, and then cinnamic acid and EDCI are added, and the mixture is stirred overnight. After the substrate is basically converted completely as monitored by TLC, a saturated NaHCO3 solution is added to quench the reaction, and then extracted with DCM, washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered and concentrated under reduced pressure. Subsequently, it is purified by silica gel chromatography, and the corresponding (3-b) to (27-b) cinnamic acid derivatives are obtained according to the different structures of the added cinnamic acid.

[0025] Preferably, in step S11, the chalactone is calculated as 10.0 g, 40.21 mmol, 1.0 equiv, the parameters of SeO2 are 2.2 g, 20.14 mmol, 0.5 equiv, and the parameters of t-BuOOH are 13.0 g, 100.68 mmol, 2.5 equiv, 70% in H2O; in step S13, the mixture is calculated as 5.0 g, 18.92 mmol, 1.0 equiv., the parameters of Et3N are 5.7 g, 56.75 mmol, 3.0 equiv.; the parameters of TESCl are 6.2 g, 56.75 mmol, 3.0 equiv.; in step S14, the compound 2-a (20 mg, 75.67 mmol, 1 equiv.) is 2 g, 5.28 mmol, 1 equiv., and the parameters of the THF / TBAF mixed solution are 1.0 M TBAF in THF, 7.92 mmol, 7.92 mL; compound 1-b is calculated as 2 g, 5.28 mmol, 1 equiv., and the parameters of the THF / TBAF mixed solution are 1.0 M TBAF in THF, 7.92 mmol, 7.92 mL.

[0026] Preferably, the compound 2-a is calculated as 20 mg, 75.67 mmol, 1 equiv., the parameters of the Et3N are 23 mg, 227.00 μmol, 3 equiv.; the parameters of the DMAP are 1 mg, 3.78 μmol, 0.05 equiv.; the EDCI is 46 mg, 227.00 μmol, 3 equiv.; the compound 2-a is calculated as 20 mg, 75.67 mmol, 1 equiv., the parameters of the Et3N are 23 mg, 227.00 μmol, 3 equiv.; the parameters of the DMAP are 1 mg, 3.78 μmol, 0.05 equiv.; the EDCI is 46 mg, 227.00 μmol, 3 equiv.

[0027] Preferably, in step S11 and step S12, washing is performed with saturated brine, drying is performed with anhydrous sodium sulfate, and purification is performed on a silica gel column by column chromatography, the silica gel column has a mesh size of 200-300, and the mobile phase is PE / EA=2 / 1; in step S13, the silica gel column has a mesh size of 200-300, and the mobile phase is PE / EA=5 / 1; in step S14, the silica gel column has a mesh size of 200-300, and the mobile phase is PE / EA=1 / 1.

[0028] The beneficial effects of the present invention are as follows: by optimizing the structure of Michelia lactone, a molecular reaction is carried out between it and a cinnamic acid unit having anti-tumor activity, thereby improving its anti-tumor performance and obtaining a highly active potential drug-forming molecule for the preparation of anti-tumor drugs and auxiliary drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figures 1 to 14 The corresponding detection spectrum of the embodiment of the present invention;

[0030] Figures 15 to 63 It is the reaction structure diagram of the present invention;

[0031] Fig.64 The table shows the inhibition rate of MCL and compounds 4-a to 27-a and 4-b to 27-b on PANC-1 cell line at a concentration of 10 μM;

[0032] Fig.65 The table shows the inhibitory effects of MCL and some compounds on PANC-1 cell line. DETAILED DESCRIPTION

[0033] In order to understand the present invention, the present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited to these embodiments.

[0034] First, the hydroxylated derivative of Michelia lactone was obtained by Riley oxidation. Since Michelia lactone has multiple allylic oxidation sites, hydroxylated derivative products with two oxidation sites, 9R-hydroxy Michelia lactone and 2R-hydroxy Michelia lactone, were obtained.

[0035] Secondly, two hydroxyl derivatives of Michelia lactone were molecularly spliced ​​with 25 cinnamic acid units with different structures to synthesize a series of Michelia lactone-cinnamic acid derivatives, and the IC of the derivatives against PANC-1 tumor cells were tested respectively. 50 Based on the comparison of activity data, two potential drug molecules 20-a and 26-a were obtained, whose anti-PANC-1 cell activity was 5 times higher than that of Michelia lactone, and their IC 50 The structure-activity relationship of Michelia lactone-cinnamic acid derivatives was preliminarily summarized.

[0036] 1. Compound Synthesis

[0037] 1. Synthesis of compounds 1-a and 1-b

[0038] MCL (10.0 g, 40.21 mmol, 1.0 equiv.) was added to a dry 500 mL three-necked round-bottom flask at room temperature, and dry DCM (200 mL) was added to dissolve it. SeO2 (2.2 g, 20.14 mmol, 0.5 equiv.) and t-BuOOH (13.0 g, 100.68 mmol, 2.5 equiv., 70% in H2O) dried over anhydrous sodium sulfate were added. The mixture was stirred at room temperature for 6 hours. After TLC monitoring showed that most of the substrate was basically converted, saturated Na2S2O3 solution (50 mL) was added to quench the reaction until a brick-red amorphous selenium precipitate appeared in the reaction solution. The reaction solution was filtered through diatomaceous earth, extracted with DCM (3×100 mL), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 2 / 1) to obtain a light yellow solid mixture (5.9 g, 55%). Since the mixture was obtained, accurate NMR data could not be obtained, and the accurate data can be found in the subsequent reaction steps.

[0039] The obtained mixture (5.0 g, 18.92 mmol, 1.0 equiv.) was added to a 250 mL round-bottom flask at 0 °C, and dried DCM (100 mL) was added to dissolve it, and dried Et3N (5.7 g, 56.75 mmol, 3.0 equiv.) was slowly added. After the reaction solution was stirred for 15 minutes, TESCl (6.2 g, 56.75 mmol, 3.0 equiv.) was added, and the mixture was stirred overnight. After the substrate was basically converted as monitored by TLC, H2O (20 mL) was added to quench the reaction, extracted with DCM (3×50 mL), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain colorless oily compound 1-a (3.0 g, 47%) and light yellow oily compound 1-b (2.5 g, 40%), respectively.

[0040] 1-a: 1H NMR(400MHz,CDCl3)δ6.17(d,J=3.5Hz,1H),5.43(d,J=3.2Hz,1H),4.25(dd,J=5.4,1.6Hz,1H),3.81(t,J=10.6Hz,1H),3.51(tt,J=10.4,2.9Hz,1H),2.92-2.97(m,J=11.3,2.7Hz,1H),2.56(s,1H),2.32(dd,J=16.8,8.7Hz,1H),2.15(ddd,J=13.6,5.4,2.3Hz,1H),1.81-1.87(m,2H),1.76(s,3H),1.51(ddd,J=13.2,11.1,1.6Hz,1H),1.30(s,3H),0.93(t,J=7.9Hz,9H),0.58(q,J=7.9Hz,6H)ppm. 13 C NMR(100MHz,CDCl3)δ169.96,139.63,135.16,133.36,118.47,84.32,80.47,72.64,57.38,41.65,38.34,33.95,30.65,22.93,22.74,6.96,5.06ppm.HRMS(ESI)m / z calcd for C 21 H 34 O4NaSi + [M+Na] + :401.2219;Found:401.2126.1-b: 1 H NMR(400MHz,CDCl3)δ6.11(d,J=3.4Hz,1H),5.40(d,J=3.2Hz,1H),4.09(d,J=5.9Hz,1H),3.52(t,J=10.5Hz,1H),3.27(ddd,J=13.8,8.8,3.3Hz,1H),2.57(s,1H),2.45(ddd,J=14.4,6.1,3.1Hz,1H),2.23(d,J=11.3Hz,1H),2.07(td,J=14.4,12.5,5.4Hz,1H),2.01–1.87(m,2H),1.62(s,3H),1.31(s,3H),1.26–1.10(m,1H),0.97(t,J=7.9Hz,9H),0.62(q,J=7.9Hz,6H)ppm. 13C NMR (100MHz, CDCl3) δ170.06,139.73,135.26,133.47,118.57,84.42,80.57,77.58,77.26,7 6.94,72.75,57.48,41.75,38.45,34.06,30.75,23.04,22.84,7.06,5.17ppm.HRMS(ESI)m / z calcd for C 21 H 34 O4NaSi + [M+Na] + :401.2219;Found:401.2128.

[0041] 2. Synthesis of compounds 2-a and 2-b

[0042] Compound 1-a (2 g, 5.28 mmol, 1 equiv.) was dissolved in a solution of THF / TBAF (1.0 M TBAF in THF, 7.92 mmol, 7.92 mL) and stirred at room temperature overnight. After the substrate was basically converted as monitored by TLC, H2O (10 mL) was added to quench the reaction, extracted with EtOAc (3×20 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column (200-300 mesh, mobile phase PE / EA=1 / 1) to obtain yellow solid compound 2-a (1.2 g, 86%). 1 H NMR (400MHz, CDCl3) δ6.19(d,J=3.4Hz,1H),5.50(d,J=3.2Hz,1H),4.29(dd,J=4.9,2.2Hz,1H),3.89–3.79(m,1H),3.41–3.29(m,1H),2.89(dt,J=11. 0,2.8Hz,1H),2.77(s,1H),2.41–2.31(m,1H),2.34–2.25(m,1H),2.22–2.1 6(m,1.9Hz,2H),1.83–1.75(m,5H),1.58–1.51(m,1H),1.26(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.87,138.85,135.57,132.89,119.63,84.00,80.32,72 .40,57.96,41.50,38.11,38.03,33.28,30.58,22.84,22.65ppm.HRMS(ESI)m / z calcd forC15H20O4NaSi + [M+Na] +:287.1254;Found:287.1264.

[0043] Compound 1-b (2 g, 5.28 mmol, 1 equiv.) was dissolved in a solution of THF / TBAF (1.0 M TBAF in THF, 7.92 mmol, 7.92 mL) and stirred at room temperature overnight. After the substrate was basically converted as monitored by TLC, H2O (10 mL) was added to quench the reaction, extracted with EtOAc (3×20 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column (200-300 mesh, mobile phase PE / EA=1 / 1) to obtain yellow solid compound 2-b (1.1 g, 79%). 1 H NMR(400MHz, CDCl3) δ6.22(d,J=3.5Hz,1H),5.52(d,J=3.2Hz,1H),4.36–4.30( m,1H),3.86(t,J=10.5Hz,1H),3.37(ddq,J=15.2,9.7,3.0Hz,1H),2.91(dq,J= 11.0,2.8Hz,1H),2.69(s,1H),2.29–2.42(m,2H),2.16–2.27(m,1H),1.82(s,3 H),1.77–1.79(m,1H)1.57(ddd,J=14.0,11.5,2.2Hz,1H),1.29(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.77,138.84,135.90,132.87,119.68,83.99,80.34,7 2.59,58.08,41.53,38.05,33.30,30.67,22.87,22.72ppm.HRMS(ESI)m / zcalcd for C15H20O4NaSi + [M+Na] + :287.1254;Found:287.1262.

[0044] 3. Synthesis of compounds 3-a and 3-b

[0045] At 0°C, compound 2-a (20 mg, 75.67 mmol, 1 equiv.) was added to a 10 mL round-bottom flask, 2 mL of DCM was added to dissolve it, Et3N (23 mg, 227.00 μmol, 3 equiv.) and DMAP (1 mg, 3.78 μmol, 0.05 equiv.) were added, and acid-1 was added after the pH value of the solution was 9-10, followed by EDCI (46 mg, 227.00 μmol, 3 equiv.), and the mixture was stirred overnight. After the substrate was basically converted as monitored by TLC, a saturated NaHCO3 solution (2 mL) was added to quench the reaction, and DCM (3×2 mL) was extracted, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid compound 3-a (30 mg, 92%). = +15.2 (c = 3.0, CHCl3). 1 H NMR (400MHz, CDCl3) δ7.68 (d, J=16.0Hz, 1H), 7.53 (dd, J=6.8, 2.9Hz, 2H), 7.4 1–7.34(m,3H),6.44(d,J=16.0Hz,1H),6.22(d,J=3.4Hz,1H),5.58(dd,J=4.9, 2.2Hz, 1H), 5.50 (d, J = 3.1Hz, 1H), 3.92 (t, J = 10.5Hz, 1H), 3.26 (tt, J = 9.9, 2. 7Hz,1H),3.00(dt,J=11.0,2.7Hz,1H),2.48–2.42(m,2H),2.29–2.20(m,1H),1 .88(dd,J=12.4,8.8Hz,1H),1.80(s,4H),1.72–1.65(m,1H),1.33(s,3H)ppm. 13CNMR(100MHz,CDCl3)δ169.41,166.52,145.61,138.93,138.34,134.22,130 .65,129.42,129.04,128.27,119.93,117.84,83.72,80.38,77.48,77.16,76. 84,73.83,58.13,42.54,38.03,30.82,30.78,22.80,22.69ppm.HRMS(ESI)m / z calcd for C 24 H 26 O5Na + [M+Na] +:417.1672;Found:417.1671.

[0046] At 0°C, compound 2-b (20 mg, 75.67 mmol, 1 equiv.) was added to a 10 mL round-bottom flask, 2 mL of DCM was added to dissolve it, Et3N (23 mg, 227.00 μmol, 3 equiv.) and DMAP (1 mg, 3.78 μmol, 0.05 equiv.) were added, and acid-1 was added after the pH value of the solution was 9-10, followed by EDCI (46 mg, 227.00 μmol, 3 equiv.), and the mixture was stirred overnight. After the substrate was basically converted as monitored by TLC, a saturated NaHCO3 solution (2 mL) was added to quench the reaction, and DCM (3×2 mL) was extracted, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase: PE / EA=4 / 1) to obtain white solid compound 3-a (26 mg, 78%). =-12.4 (c = 3.0, CHCl3). 1 H NMR(400MHz, CDCl3) δ7.67(d,J=16.0Hz,1H),7.55–7.49(m,2H),7.42–7.33(m,3H),6.41(d,J=16.0Hz ,1H),6.25(d,J=3.3Hz,1H),5.83(d,J=6.5Hz,1H),5.54(d,J=3.0Hz,1H),3.98(t,J=10.3Hz,1H),2.87 –2.81(m,1H),2.75–2.68(m,1H),2.36(q,J=4.2,3.5Hz,2H),2.25–2.19(m,1H),2.12–2.18(m,J=13.6, 4.1,2.0Hz,1H),2.00(d,J=14.4Hz,1H),1.74(d,J=2.6Hz,3H),1.50–1.44(m,1H),1.25(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.76,166.41,145.26,140.74,138.64,134.38,131.48,130.56,129.04,128.24, 119.86,118.11,84.02,79.91,74.19,59.24,49.75,46.19,35.62,25.43,24.82,24.36ppm.HRMS(ESI)m / z calcd for C 24 H 26 O5Na+ [M+Na] + :417.1672;Found:417.1672.

[0047] 4. Synthesis of compounds 4-a and 4-b

[0048] The synthesis of compound 4-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 5 / 1) to obtain white solid 4-a (33 mg, 92%). = +18.9 (c = 0.3, CHCl3). 1 H NMR (400MHz, CDCl3) δ7.61 (d, J=16.0Hz, 1H), 7.56–7.48 (m, 2H), 7.44–7.35 (m, 2H), 6.43 (d, J= 16.0Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.92(d d,J=11.0,10.0Hz,1H),3.21–3.29(m,1H),2.96–3.02(m,1H),2.50–2.39(m,2H),2.31–2.20(m ,1H),1.96–1.82(m,1H),1.80(s,3H),1.69(ddd,J=14.2,11.6,2.2Hz,1H),1.33(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.26,166.17,144.12,138.99,138.25,133.08,132.23,129.54,129.27,124.87,119 .84,118.49,83.60,80.31,73.93,58.08,42.49,37.95,30.75,30.68,22.72,22.59ppm.HRMS(ESI)m / zcalcd for C 24 H 25 BrO5Na + [M+Na] + :495.0778;Found:495.0776.

[0049] The synthesis of compound 4-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain white solid 4-b (31 mg, 87%). =-1.03 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.60(d,J=16.0Hz,1H),7.51(s,1H),7.39(dd,J=7.2,1.5Hz,1H),7.36–7.29(m,2 H),6.43–6.36(m,1H),6.25(d,J=3.3Hz,1H),5.82(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),3.97(t,J=1 0.3Hz,1H),2.84(d,J=10.8Hz,1H),2.75–2.66(m,1H),2.51(s,1H),2.37(t,J=5.4Hz,2H),2.22(dd,J= 14.5,6.7Hz,1H),2.19–2.11(m,1H),1.99(d,J=14.4Hz,1H),1.73(d,J=2.6Hz,3H),1.53(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.72,165.97,143.61,140.86,138.61,136.21,135.07,131.39,130.41,130.29,127.89,1 26.50,119.88,119.61,83.99,79.89,74.43,59.23,49.74,46.17,35.63,25.43,24.84,24.37.HRMS(ESI)m / zcalcd for C 24 H 25 BrO5Na + [M+Na] + :495.0778;Found:495.0779.

[0050] 5. Synthesis of Compounds 5-a and 5-b

[0051] The synthesis of compound 5-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 5 / 1) to obtain white solid 5-a (28 mg, 88%). = +19.07 (c = 0.3CHCl3). 1H NMR(400MHz, CDCl3) δ7.99(d,J=16.2Hz,1H),7.50(dd,J=7.7,1.7Hz,1H),7.36(ddd,J=8.3,7.4,1.7Hz,1H), 6.99–6.90(m,2H),6.54(d,J=16.1Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.2Hz,1H),5.50(d,J=3.1 Hz,1H),3.94(d,J=10.0Hz,1H),3.90(s,3H),3.32–3.24(m,1H),2.99–3.03(m,1H),2.50–2.41(m,2H),2.27( q,J=8.6,7.4Hz,1H),1.95–1.84(m,2H),1.81(td,J=1.7,0.8Hz,3H),1.71–1.65(m,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.51,167.14,158.60,141.29,138.77,138.48,131.90,129.66,129.44,123.24,120.88,119 .92,118.36,111.29,83.86,80.44,73.62,58.16,55.67,52.47,42.62,38.10,30.85,22.86,22.71ppm.HRMS(ESI)m / z Calculated for C 25 H 28 O6Na + [M+Na] + :447.1778;Found:447.1775.

[0052] The synthesis of compound 5-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 5-b (31 mg, 84%). =-6.25 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ8.00(d,J=16.1Hz,1H),7.51(dd,J=7.7,1.8Hz,1H),7.35(ddd,J=9.0,7.5,1.7H z,1H),6.97–6.90(m,2H),6.25(d,J=3.4Hz,1H),5.84(d,J=6.6Hz,1H),5.54(d,J=3.1Hz,1H),3.98(t, J=10.3Hz,1H),3.89(s,3H),2.84(d,J=10.7Hz,1H),2.71(t,J=12.0Hz,1H),2.36(d,J=6.5Hz,2H),2.2 2(dd,J=14.4,6.6Hz,1H),2.15(dd,J=13.9,2.2Hz,1H),1.98(s,1H),1.74(S,3H),1.52(S,3H)ppm.13C NMR (100MHz, CDCl3) δ174.46,166.94,149.03,140.74,140.60,139.10,138.74,131.78,131.66,129.06,120.85,119 .79,118.55,111.33,84.09,79.99,73.96,59.31,55.69,49.83,46.26,35.65,25.47,24.81,24.38ppm.HRMS(ESI)m / z calcd for C 25 H 28 O6Na + [M+Na] + :447.1778;Found:447.1774.

[0053] 6. Synthesis of Compounds 6-a and 6-b

[0054] The synthesis of compound 6-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 6-a (33 mg, 91%). =+18.72(c=0.3,CHCl3).1H NMR (400MHz, CDCl3) δ7.64(d,J=15.9Hz,1H),7.49(d,J=8.8Hz,2H),6.91(d,J=8.8Hz,2H),6.31(d,J=15.9H z,1H),6.23(d,J=3.4Hz,1H),5.57(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.93(t,J=10.5Hz,1H),3. 84(s,3H),3.32–3.18(m,1H),3.05–2.96(m,1H),2.64(s,1H),2.50–2.44(m,1H),2.47–2.39(m,1H),2.32–2 .18(m,1H),1.97–1.80(m,2H),1.81–1.80(m,3H),1.68(ddd,J=14.3,11.6,2.2Hz,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.73,166.74,161.64,144.91,140.59,138.73,131.67,129.93,127.18,119.77,115 .61,114.49,84.06,79.95,74.00,59.30,55.53,49.82,46.26,35.65,25.48,24.85,24.34ppm.HRMS(ESI)m / z calcd for C 25 H 28 O6Na + [M+Na] + :447.1778;Found:447.1776.

[0055] The synthesis of compound 6-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain white solid 6-b (31 mg, 85%). =-1.87(c=0.3,CHCl3).1H NMR (400MHz, CDCl3) δ7.62(d,J=15.9Hz,1H),7.47(d,J=8.3Hz,2H),6.90(d,J=8.4Hz,2H),6.27(d,J= 16.1Hz,1H),5.82(d,J=6.6Hz,1H),5.56–5.51(m,1H),3.97(t,J=10.3Hz,1H),3.84(s,3H),2.84(d,J =10.8Hz,1H),2.71(t,J=10.7Hz,1H),2.49(s,1H),2.36(t,J=5.4Hz,2H),2.21(dd,J=14.4,6.7Hz,1H ),2.15(d,J=13.7Hz,1H),1.99(d,J=14.4Hz,1H),1.74(S,3H),1.54(s,3H),1.52–1.36(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.73,166.74,161.64,144.91,140.59,138.73,131.67,129.93,127.18,119.77,115 .61,114.49,84.06,79.95,74.00,59.30,55.53,49.82,46.26,35.65,25.48,24.85,24.34ppm.HRMS(ESI)m / z calcdfor C25H28O6Na + [M+Na]+:447.1778; Found:447.1777.

[0056] 7. Synthesis of compounds 7-a and 7-b

[0057] The synthesis of compound 7-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 7-a (31 mg, 88%). =+20.0(c=0.3,CHCl3).1H NMR (400MHz, CDCl3) δ8.01(d,J=15.9Hz,1H),7.57(d,J=7.7Hz,1H),7.30(d,J=7.6Hz,1H),7.21(d,J=7.4Hz,2H), 6.37(dd,J=15.8,2.0Hz,1H),6.24(d,J=3.1Hz,1H),5.61–5.56(m,1H),5.51(d,J=2.8Hz,1H),3.93(t,J=10.5Hz, 1H),3.27(t,J=11.0Hz,1H),3.00(d,J=10.1Hz,1H),2.63(s,1H),2.50–2.47(m,1H),2.45(s,3H),2.43(s,1H),2. 33–2.23(m,1H),1.97–1.83(m,1H),1.82(s,3H),1.70(dd,J=14.5,11.8Hz,1H),1.59(s,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.44,166.70,143.42,138.98,138.43,137.92,133.18,131.02,130.45,129.53,126.60, 126.54,119.95,118.73,83.79,80.43,73.88,58.22,42.63,38.10,30.86,22.86,22.72,19.94ppm.HRMS(ESI)m / z calcd for C 25 H28O5Na + [M+Na] + :431.1829;Found:431.1824.

[0058] The synthesis of compound 7-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain white solid 7-b (30 mg, 84%). =-2.47 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.98(d,J=15.8Hz,1H),7.55(d,J=7.8Hz,1H),7.28(d,J=7.7Hz,1H),7.20(d,J=6.9Hz,2H),6.3 3(d,J=15.9Hz,1H),6.25(t,J=2.3Hz,1H),5.84(d,J=6.5Hz,1H),5.54(d,J=0.3Hz,1H),3.97(t,J=10.3Hz,1H),2.84( d,J=10.7Hz,1H),2.71(t,J=10.7Hz,1H),2.51(s,1H),2.43(s,3H),2.37(t,J=5.4Hz,2H),2.22(dd,J=14.4,6.6Hz,1H ),2.15(d,J=13.9Hz,1H),2.00(d,J=14.4Hz,1H),1.75(d,J=2.5Hz,3H),1.55(s,3H),1.46(tt,J=9.5,3.9Hz,1H).13C NMR (100MHz, CDCl3) δ169.73,166.46,142.96,140.72,138.66,137.84,133.31,131.54,130.99,130.31,126.47,126 .46,119.82,119.01,84.03,79.93,74.14,59.26,49.78,46.22,35.63,25.45,24.79,24.37,19.88ppm.HRMS(ESI)m / z calcdfor C 25 H 28 O5Na + [M+Na] + :431.1829;Found:431.1828.

[0059] 8. Synthesis of Compounds 8-a and 8-b

[0060] The synthesis of compound 8-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 8-a (42 mg, 90%). = +18.72 (c = 0.3, CHCl3). 1H NMR(400MHz, CDCl3)δ8.09(dq,J=15.8,2.2Hz,1H),7.80–7.68(m,2H),7.62–7.53(m,1H),7.49(t,J=7.6Hz,1H),6 .43(d,J=15.7Hz,1H),6.24(d,J=3.3Hz,1H),5.59(dd,J=4.9,2.1Hz,1H),5.52(d,J=3.1Hz,1H),3.93(t,J=10.5H z,1H),3.31–3.19(m,1H),2.98(dt,J=11.0,2.8Hz,1H),2.62(s,1H),2.52–2.39(m,2H),2.26(q,J=16.9,13.6Hz, 1H),1.95–1.86(m,1H),1.88–1.82(m,1H),1.82(s,3H),1.70(ddd,J=14.3,11.7,2.2Hz,1H),1.34(s,3H)ppm.13C NMR (101MHz, CDCl3) δ169.37,165.63,141.10,141.07,141.05,139.18,138.31, 133.08,132.23,129.96,129.48,129.37,129.18,128.88,128.58,128.08,127.9 4,126.43,126.38,126.32,126.27,125.36,122.63,122.01,119.92,83.66,80.3 8,76.84,74.22,58.14,42.59,38.06,30.83,30.74,22.80,22.67.HRMS(ESI)m / z calcd for C 25 H 25 F3O5Na + [M+Na] + :485.1546;Found:485.1542.

[0061] The synthesis of compound 8-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 8-b (40 mg, 86%). =-6.25 (c = 0.4, CHCl3). 1H NMR(400MHz, CDCl3)δ8.04(dd,J=15.8,2.2Hz,1H),7.75–7.67(m,2H),7.60–7.53(m,1H),7. 51–7.44(m,1H),6.38(d,J=15.8Hz,1H),6.25(d,J=3.3Hz,1H),5.85(d,J=6.5Hz,1H),5.54(d ,J=0.3Hz,1H),3.96(t,J=10.3Hz,1H),2.84(d,J=9.9Hz,1H),2.71(td,J=10.7,10.1,2.6Hz, 1H),2.50(s,1H),2.37(t,J=5.2Hz,2H),2.26–2.20(m,1H),2.15(dtd,J=13.7,4.0,2.1Hz,1H ),2.01(d,J=14.4Hz,1H),1.75(d,J=2.6Hz,3H),1.55(s,3H),1.52–1.38(m,1H).13CNMR(10 0MHz, CDCl3) δ169.72,165.39,140.98,140.52,140.50,138.62,133.25,132.22,131.35,129 .86,129.13,128.83,127.92,126.43,126.37,126.32,126.26,125.38,122.66,122.37,119. 83,84.02,79.89,74.48,59.22,49.75,46.17,35.62,25.44,24.71,24.34ppm.HRMS(ESI)m / z calcd for C 25 H 25 F3O5Na + [M+Na] + :485.1546;Found:485.1542.

[0062] 9. Synthesis of Compounds 9-a and 9-b

[0063] The synthesis of compound 9-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 9-a (32 mg, 91%). = +17.8 (c = 0.3, CHCl3). 1H NMR(400MHz, CDCl3)δ7.64(d,J=15.9Hz,1H),7.37(td,J=7.9,5.6Hz,1H),7.34–7.27(m,1H),7.2 7–7.17(m,1H),7.09(tdd,J=8.1,2.8,1.1Hz,1H),6.44(d,J=16.0Hz,1H),6.24(d,J=3.4Hz,1H), 5.59(dd,J=4.8,2.2Hz,1H),5.50(d,J=3.1Hz,1H),3.93(t,J=10.5Hz,1H),3.31–3.20(m,1H),3. 00(dt,J=11.0,2.8Hz,1H),2.64(s,1H),2.54–2.44(m,1H),2.47–2.39(m,1H),2.26(q,J=17.0,1 3.9Hz,1H),1.87–1.82(m,2H),1.81(S,3H),1.70(ddd,J=14.2,11.5,2.2Hz,1H),1.34(s,3H)ppm .13CNMR(100MHz,CDCl3)δ169.37,166.17,164.34,161.88,144.20,144.18,139.13,138.34,136 .53,136.45,130.67,130.59,129.32,124.29,124.26,119.96,119.33,117.64,117.42,114.64, 114.41,83.70,80.40,74.10,58.19,42.57,38.05,30.86,30.79,22.82,22.70ppm.HRMS(ESI)m / z calcd for C 24 H 25 F5N + [M+Na] + :435.1578;Found:435.1574.

[0064] The synthesis of compound 9-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 8-b (30 mg, 84%). =-1.93 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.62(d,J=15.9Hz,1H),7.35(td,J=7.9,5.6Hz,1H),7.29(dt,J=7.8,1.3Hz,1H),7.22(dt,J=9.7,2.1Hz,1H),7. 08(tdd,J=8.3,2.6,1.1Hz,1H),6.39(d,J=16.0Hz,1H),6.25(d,J=3.3Hz,1H),5.83(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),3.96(t,J =10.3Hz,1H),2.84(dt,J=10.7,2.4Hz,1H),2.74–2.66(m,1H),2.52(s,1H),2.36(t,J=5.5Hz,2H),2.22(dd,J=14.5,6.7Hz,1H),2.15 (dtd,J=13.9,4.0,2.1Hz,1H),1.99(d,J=14.4Hz,1H),1.73(d,J=2.6Hz,3H),1.53(s,3H),1.47(ddt,J=11.0,9.4,3.9Hz,1H)ppm.13C NMR (100MHz, CDCl3) δ169.72,166.02,164.35,161.89,143.85,143.82,140.86,138.61,136.66,136.59,131.40,130.64,130.56,124.31,124. 28,119.87,119.53,117.53,117.31,114.53,114.32,83.99,79.88,74. 41,59.23,49.74,46.18,35.62,25.43,24.83,24.37ppm.HRMS(ESI)m / z calcd for C 24 H 25 F5N + [M+Na] + :435.1578;Found:435.1576.

[0065] 11. Synthesis of compounds 11-a and 11-b

[0066] The synthesis of compound 11-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 11-a (32 mg, 86%). = +18.73 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.64 (d, J=16.0Hz, 1H), 7.55–7.50 (m, 2H), 7.11–7.06 (m ,2H),6.36(d,J=16.1Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1 H),5.50(d,J=3.1Hz,1H),3.96–3.89(m,1H),3.29–3.22(m,1H),2.99(dt,J=1 1.1,2.8Hz,1H),2.45(ddd,J=14.6,4.8,2.3Hz,2H),2.30–2.21(m,1H),1.95– 1.82(m,2H),1.80(s,3H),1.72–1.66(m,1H),1.34(s,3H)ppm.13CNMR(100MHz , CDCl3)δ169.40,166.43,165.42,162.92,144.32,139.03,138.39,130.52,1 30.25,130.16,129.45,119.95,117.67,117.65,116.38,116.16,83.75,80.4 3,73.94,58.20,42.61,38.08,30.87,30.81,22.84,22.71ppm.HRMS(ESI)m / z Calculate for C 24 H 25 F5N + [M+Na] + :435.1578;Found:435.1580.

[0067] The synthesis of compound 11-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 11-b (28 mg, 79%). =-1.93 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.63(d,J=15.8Hz,1H),7.50(d,J=7.4Hz,2H),7.07(t,J=8.6Hz,2H),6.32(d,J= 16.0Hz,1H),6.25(s,1H),5.82(d,J=6.5Hz,1H),5.54(dt,J=2.9,1.2Hz,1H),3.96(t,J=10.3Hz,1H),2 .83(d,J=10.9Hz,1H),2.70(t,J=10.7Hz,1H),2.36(t,J=5.5Hz,2H),2.22(dd,J=14.7,6.5Hz,1H),2.1 5(dd,J=13.5,2.8Hz,1H),1.99(d,J=14.4Hz,1H),1.73(s,3H),1.53(s,3H),1.50–1.40(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.73,166.27,165.33,162.83,143.93,140.76,138.63,131.48,130.64,130.17,130.09,119.85, 117.89,117.86,116.31,116.09,84.00,79.89,74.25,59.24,49.75,46.21,35.62,25.44,24.82,24.35ppm.HRMS(ESI)m / z calcd for C 24 H 25 F5N + [M+Na] + :435.1578; Found:435.1576.12, Synthesis of Compounds 12-a and 12-b

[0068] The synthesis of compound 12-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 12-a (38 mg, 91%). = +17.57 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ8.06 (d, J=16.2Hz, 1H), 7.52 (dd, J=7.8, 1.7Hz, 1H), 7.33 (ddd, J=8.3, 7.3, 1.7Hz, 1H), 6.99–6.85 (m, 2H), 6. 50(d,J=16.2Hz,1H),6.23(d,J=3.4Hz,1H),5.57(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),4.10(q,J=7.0Hz,2H),3.93(dd,J=1 1.0,10.1Hz,1H),3.34–3.23(m,1H),3.00(dt,J=10.9,2.8Hz,1H),2.63(s,1H),2.50–2.46(m,1H),2.45–2.39(m,1H),2.25(dt,J= 17.3,10.9Hz,1H),1.95–1.84(m,1H),1.81(s,3H),1.68(ddd,J=14.2,11.6,2.2Hz,1H),1.47(t,J=6.9Hz,3H),1.34(s,3H)ppm.13C NMR (101MHz, CDCl3) δ169.49,167.01,157.86,141.12,138.74,138.47,131.94,129.75,128.78,123.19,120.72,119.90 ,117.85,112.18,83.85,80.43,73.54,64.12,58.15,42.67,38.09,30.82,30.81,22.86,22.72,14.96ppm.HRMS(ESI)m / z calcd for C 26 H30O6Na + [M+Na] + :461.1935;Found:461.1935.

[0069] The synthesis of compound 12-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 12-b (33 mg, 84%). =-1.72 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ8.04(d,J=16.1Hz,1H),7.51(d,J=7.6Hz,1H),7.32(t,J=8.2Hz,1H),6.97–6.86(m,2H),6.46( d,J=16.2Hz,1H),6.25(d,J=3.4Hz,1H),5.85(d,J=6.5Hz,1H),5.54(d,J=0.3Hz,1H),4.09(q,J=7.1Hz,2H),3.97(t, J=10.3Hz,1H),2.84(d,J=10.8Hz,1H),2.79–2.65(m,1H),2.36(t,J=5.5Hz,2H),2.21(dd,J=14.4,6.7Hz,1H),2.17 –2.10(m,1H),1.99(d,J=14.3Hz,1H),1.74(d,J=2.5Hz,3H),1.56(s,3H),1.45(t,J=7.0Hz,3H),1.25(s,1H)ppm.13C NMR (100MHz, CDCl3) δ169.80,166.85,157.82,140.61,140.58,138.71,131.78,131.66,128.64,123.39,120.71,119.81, 118.25,112.24,84.12,80.00,73.84,64.15,59.29,49.82,46.26,35.63,25.47,24.79,24.38,14.94.HRMS(ESI)m / zcalcd for C 26 H30O6Na + [M+Na] + :461.1935;Found:461.1932.

[0070] 13. Synthesis of compounds 13-a and 13-b

[0071] The synthesis of compound 13-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 13-a (33 mg, 82%). = +21.9 (c = 0.33, CHCl3). 1H NMR (400MHz, CDCl3) δ7.69(d,J=16.2Hz,1H),7.64(s,4H),6.52(d,J=16.0Hz,1 H),6.24(d,J=3.3Hz,1H),5.59(dd,J=4.8,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3. 93(t,J=10.5Hz,1H),3.29–3.22(m,1H),3.00(dt,J=11.0,2.7Hz,1H),2.49–2.4 1(m,2H),2.27(d,J=10.7Hz,1H),1.89(ddd,J=25.3,12.6,8.2Hz,2H),1.81(s,3 H),1.74–1.67(m,1H),1.34(s,3H)ppm.13CNMR(100MHz,CDCl3)δ169.34,165.9 9,143.73,139.28,138.34,137.64,132.30,131.98,129.30,128.42,128.41,12 6.12,126.08,126.04,126.00,125.25,122.54,120.51,119.97,83.69,80.44,7 4.29,58.23,42.62,38.08,30.90,30.79,22.84,22.72ppm.HRMS(ESI)m / zcalcd for C 25 H 25 F3O5Na + [M+Na] + :485.1546;Found:485.1544.

[0072] The synthesis of compound 13-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 13-b (28 mg, 72%). =-2.21 (c = 0.33, CHCl3). 1H NMR (400MHz, CDCl3) δ7.68(d,J=16.2Hz,1H),7.63(s,4H),6.48(d,J=16.0Hz,1H),6.26(d,J=3. 3Hz,1H),5.84(d,J=6.5Hz,1H),5.54(d,J=0.3Hz,1H),3.97(t,J=10.3Hz,1H),2.87–2.81(m,1H) ,2.75–2.67(m,1H),2.37(t,J=5.7Hz,2H),2.24(dd,J=14.5,6.7Hz,1H),2.19–2.13(m,1H),2.00 (d,J=14.4Hz,1H),1.74(d,J=2.6Hz,3H),1.54(s,3H),1.46(ddd,J=9.2,7.1,4.3Hz,1H)ppm.13C NMR (100MHz, CDCl3) δ169.68,165.83,143.38,140.95,138.61,137.77,133.78,132.20,131.72,131.40,128.38,126.07,126.03,12 6.00,125.96,125.39,125.27,120.72,119.88,83.98,79.88,74.59,59.26,49.77,46.21,35.65,25.46,24.85,24.38.HRMS(ESI)m / z calcd for C 25 H 25 F3O5Na + [M+Na] + :485.1546;Found:485.1548.

[0073] 14. Synthesis of compounds 14-a and 14-b

[0074] The synthesis of compound 14-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 5 / 1) to obtain white solid 14-a (33 mg, 83%). = +22.0 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.63(d,J=16.0Hz,1H),7.46(d,J=8.6Hz,2H),7.36(d,J=8.5Hz,2H),6.41(d,J =16.0Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.95–3.89(m ,1H),3.25(ddt,J=12.3,10.0,2.7Hz,1H),2.99(dt,J=10.9,2.8Hz,1H),2.49–2.44(m,1H),2.44–2. 40(m,1H),2.30–2.21(m,1H),1.96–1.81(m,2H),1.80(s,3H),1.72–1.66(m,1H),1.33(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.38,166.30,144.16,139.09,138.37,136.62,132.77,129.45,129.40,129.38, 119.95,118.49,83.72,80.43,74.03,58.20,42.61,38.07,30.87,30.80,22.84,22.71ppm.HRMS(ESI)m / z calcd forC 24 H 25 ClO5Na + [M+Na] + :451.1283;Found:451.1286.

[0075] The synthesis of compound 14-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 5 / 1) to obtain white solid 14-a (33 mg, 83%). = +22.0 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.63(d,J=16.0Hz,1H),7.46(d,J=8.6Hz,2H),7.36(d,J=8.5Hz,2H),6.41(d,J =16.0Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.95–3.89(m ,1H),3.25(ddt,J=12.3,10.0,2.7Hz,1H),2.99(dt,J=10.9,2.8Hz,1H),2.49–2.44(m,1H),2.44–2. 40(m,1H),2.30–2.21(m,1H),1.96–1.81(m,2H),1.80(s,3H),1.72–1.66(m,1H),1.33(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.38,166.30,144.16,139.09,138.37,136.62,132.77,129.45,129.40,129.38, 119.95,118.49,83.72,80.43,74.03,58.20,42.61,38.07,30.87,30.80,22.84,22.71ppm.HRMS(ESI)m / z calcd forC 24 H 25 ClO5Na + [M+Na] + :451.1283;Found:451.1286.

[0076] 15. Synthesis of compounds 15-a and 15-b

[0077] The synthesis of compound 15-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain white solid 15-a (33 mg, 65%). = +21.3 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.65(d,J=16.1Hz,1H),7.54(d,J=7.4Hz,2H),7.12(d,J=7.3Hz,2H),6.39(d d,J=16.0,0.9Hz,1H),6.22(t,J=1.8Hz,1H),5.57(dt,J=4.9,2.3Hz,1H),5.51–5.48(m,1H),3.92( t,J=10.5Hz,1H),3.25(ddd,J=12.5,10.2,2.7Hz,1H),2.99(dt,J=10.9,2.6Hz,1H),2.48–2.40(m, 2H),2.30(d,J=1.5Hz,3H),1.97–1.81(m,2H),1.80(s,3H),1.78–1.60(m,2H),1.33(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.41,169.22,166.42,152.39,144.48,139.00,138.36,131.97,129.44,129.41,122.31,11 9.95,118.02,83.73,80.41,73.94,58.17,42.58,38.06,30.84,30.81,22.82,22.70,21.25pmm.HRMS(ESI)m / zcalcd for C 26 H 28 O7 + [M+Na] + :475.1727;Found:475.1728.

[0078] The synthesis of compound 15-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain white solid 15-b (31 mg, 85%). =-1.75 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.65(d,J=16.0Hz,1H),7.54(d,J=8.5Hz,2H),7.12(d,J=8.6Hz,2H),6.36(d,J=16 .0Hz,1H),6.25(d,J=3.3Hz,1H),5.83(d,J=6.5Hz,1H),5.54(d,J=0.3Hz,1H),4.00–3.94(m,1H),2.84( d,J=11.0Hz,1H),2.74–2.68(m,1H),2.36(d,J=5.4Hz,2H),2.31(s,3H),2.22(dd,J=14.5,6.6Hz,1H),2 .17–2.13(m,1H),2.00(d,J=14.4Hz,1H),1.74(d,J=2.7Hz,3H),1.54(s,3H),1.48–1.41(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.74,169.26,166.28,152.33,144.13,140.78,138.67,132.14,131.50,129.39,122.30, 119.84,118.30,84.03,79.92,74.28,59.27,49.79,46.21,35.65,25.46,24.84,24.37,21.28ppm.HRMS(ESI)m / z calcd for C 26 H 28 O7 + [M+Na] + :475.1727; Found:475.1731.16, Synthesis of Compounds 16-a and 16-b

[0079] The synthesis of compound 16-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 5 / 1) to obtain a white solid 16-a (31 mg, 87%). = +19.5 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.65(d,J=15.9Hz,1H),7.29(d,J=8.0Hz,1H),7.12(dt,J=7.6,1.3Hz,1H),7.05(t,J=2.1Hz,1H) ,6.94(ddd,J=8.3,2.6,1.0Hz,1H),6.42(d,J=16.0Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1H),5.50(d ,J=3.1Hz,1H),3.96–3.89(m,1H),3.84(s,3H),3.27(ddd,J=12.2,7.9,2.6Hz,1H),3.01(dt,J=11.0,2.8Hz,1H),2.49 –2.45(m,1H),2.43(dd,J=6.0,3.6Hz,1H),1.95–1.83(m,2H),1.81(s,3H),1.69(d,J=2.6Hz,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.43,166.51,160.07,145.60,139.00,138.39,135.62,130.08,129.48,121.08,119.97,118 .14,116.78,112.88,83.77,80.44,73.89,58.18,55.48,42.61,38.08,30.87,30.82,22.85,22.72ppm.HRMS(ESI)m / z calcd forC 25 H 28 O6Na + [M+Na] + :447.1778;Found:447.1778.

[0080] The synthesis of compound 16-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain white solid 16-b (27 mg, 75%). =-2.17 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.63(d,J=15.9Hz,1H),7.29(t,J=7.9Hz,1H),7.11(d,J=7.6Hz,1H),7.03(s,1H),6.93(ddd,J=8. 2,2.6,0.9Hz,1H),6.38(d,J=16.0Hz,1H),6.24(d,J=3.3Hz,1H),5.82(d,J=6.6Hz,1H),5.53(d,J=3.1Hz,1H),3.99–3.9 4(m,1H),3.82(s,3H),2.84(dt,J=10.5,2.3Hz,1H),2.73–2.67(m,1H),2.36(dd,J=6.8,4.3Hz,2H),2.24–2.19(m,1H),2 .17–2.12(m,1H),1.99(d,J=14.4Hz,1H),1.73(d,J=2.6Hz,3H),1.54(s,3H),1.45(ddt,J=12.3,6.0,1.9Hz,1H)ppm.13C NMR (100MHz, CDCl3) δ169.65,166.24,159.92,145.07,140.64,138.53,135.62,131.36,129.92,120.86,119.72,118.28 ,116.29,112.98,83.90,79.80,74.12,59.12,55.34,49.64,46.10,35.50,25.32,24.70,24.24ppm.HRMS(ESI)m / zcalcd for C 25 H 28 O6Na + [M+Na] + :447.1778;Found:447.1777.

[0081] 17. Synthesis of compounds 17-a and 17-b

[0082] The synthesis of compound 17-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain white solid 17-a (25 mg, 89%). = +17.6 (c = 0.3, CHCl3). 1H NMR(400MHz, CDCl3)δ7.61(d,J=16.0Hz,1H),7.52(q,J=1.6Hz,1H),7.44–7.28(m,3H),6.45(d ,J=16.0Hz,1H),6.24(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.2Hz,1H),5.50(d,J=3.1Hz,1H),3.9 3(dd,J=10.9,10.0Hz,1H),3.32–3.20(m,1H),3.00(dt,J=11.1,2.8Hz,1H),2.49–2.40(m,2H) ,2.28–2.23(m,1H),1.93–1.82(m,2H),1.81(s,3H),1.69(d,J=2.5Hz,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.72,166.14,156.45,143.89,140.84,138.63,133.34,132.31,131.47,119.88,118.83, 115.36,111.55,104.16,84.01,79.91,74.38,59.26,49.77,46.21,35.65,25.46,24.85,24.38ppm.HRMS(ESI)m / z calcd for C 24 H 25 ClO5Na + [M+Na] + :451.1283;Found:451.1276.

[0083] The synthesis of compound 17-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain white solid 17-b (22 mg, 76%). =-2.07 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.60(d,J=16.0Hz,1H),7.56–7.48(m,2H),7.39(d,J=8.4Hz,2H),6.39(d,J=16.0H z,1H),6.25(d,J=3.3Hz,1H),5.83(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),3.96(t,J=10.3Hz,1H),2.84( d,J=10.7Hz,1H),2.71(t,J=11.0Hz,1H),2.36(d,J=6.5Hz,2H),2.22(dd,J=14.4,6.6Hz,1H),2.15(dd,J =14.0,2.5Hz,1H),1.99(d,J=14.3Hz,1H),1.74(d,J=2.6Hz,3H),1.54(s,3H),1.50–1.41(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.72,166.14,156.45,143.89,140.84,138.63,133.34,132.31,131.47,119.88,118.83, 115.36,111.55,104.16,84.01,79.91,74.38,59.26,49.77,46.21,35.65,25.46,24.85,24.38ppm.HRMS(ESI)m / z calcd for C 24 H 25 ClO5Na + [M+Na] + :451.1283; Found:451.1277

[0084] 18. Synthesis of compounds 18-a and 18-b

[0085] The synthesis of compound 18-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain a white solid 18-a (23 mg, 85%). = +18.4 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.67(d,J=16.0Hz,1H),7.47(d,J=8.3Hz,2H),7.24(s,1H),6.40(d,J=16.0Hz,1H),6.23 (d,J=3.4Hz,1H),5.58(dd,J=4.8,2.2Hz,1H),5.50(d,J=3.1Hz,1H),3.93(dd,J=11.0,10.0Hz,1H),3.32–3.21 (m,1H),3.01(dt,J=10.9,2.7Hz,1H),2.93(p,J=6.9Hz,1H),2.51–2.40(m,2H),2.26(q,J=15.9,13.4Hz,1H),1 .97–1.83(m,2H),1.81(s,3H),1.69(ddd,J=14.3,11.6,2.2Hz,1H),1.34(s,3H),1.26(d,J=6.9Hz,7H)ppm.13C NMR (101MHz, CDCl3) δ169.47,166.81,152.08,145.73,138.89,138.43,131.93,129.55,128.45,127.22,119.98,116.7 9,83.83,80.44,77.48,77.16,76.84,73.77,58.20,42.61,38.08,34.25,30.87,23.89,22.86,22.73ppm.HRMS(ESI)m / z calcd forC 27 H 32 O5Na + [M+Na] + :459.2142;Found:459.2140.

[0086] The synthesis of compound 18-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain a white solid 18-b (21 mg, 76%). =-2.24 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.65(d,J=16.0Hz,1H),7.46(dd,J=8.3,2.1Hz,2H),7.24(d,J=8.2Hz,2H),6.36(d,J=16.0 Hz,1H),6.25(d,J=3.3Hz,1H),5.82(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),3.98(t,J=10.3Hz,1H),2.92(p,J=6. 9Hz,1H),2.84(d,J=10.6Hz,1H),2.77–2.65(m,1H),2.23(d,J=6.7Hz,1H),2.20(d,J=6.7Hz,1H),2.17–2.12(m, 1H),2.00(d,J=14.4Hz,1H),1.74(d,J=2.6Hz,3H),1.54(s,3H),1.53–1.38(m,1H),1.25(d,J=6.8Hz,7H)ppm.13C NMR (101MHz, CDCl3) δ169.76,166.62,151.92,145.27,140.65,138.68,132.05,131.55,128.36,127.16,119.81 ,117.07,84.04,79.92,74.09,59.26,49.77,46.21,35.63,34.22,25.45,24.81,24.34,23.89ppm.HRMS(ESI)m / z calcd for C 27 H 32 O5Na + [M+Na] + :459.2142;Found:459.2140.

[0087] 19. Synthesis of Compound 19-a

[0088] The synthesis of compound 19-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA = 4 / 1) to obtain a white solid 19-a (23 mg, 85%). = +15.4 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.64(d,J=15.9Hz,1H),7.47(d,J=2.1Hz,2H),6.93–6.85(m,2H),6.30(d,J=15.9Hz ,1H),6.23(d,J=3.4Hz,1H),5.57(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),4.07(q,J=7.0Hz,2H),3.9 3(dd,J=11.0,10.0Hz,1H),3.31–3.22(m,1H),3.04–2.97(m,1H),2.50–2.39(m,2H),2.32–2.23(m,1H),1. 96–1.83(m,2H),1.80(s,3H),1.68(ddd,J=14.1,11.6,2.2Hz,1H),1.43(t,J=7.0Hz,3H),1.34(s,3H).13C NMR (100MHz, CDCl3) δ169.36,166.81,161.03,145.28,138.66,138.31,132.47,129.90,129.49,126.69,119.8 4,114.99,114.85,83.71,80.31,73.47,63.65,58.06,42.48,37.94,30.73,22.72,22.58,14.73.HRMS(ESI)m / z calcd for C 27 H 32 O5Na + [M+Na] + :461.1935;Found:461.1931.

[0089] 20. Synthesis of Compounds 20-a and 20-b

[0090] The synthesis of compound 20-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain a white solid 20-a (32 mg, 89%). = +15.5 (c = 0.33, CHCl3). 1H NMR (400MHz, CDCl3) δ7.69–7.59(m,5H),6.48(d,J=16.0Hz,1H),6.25(d,J=3.4Hz,1H), 5.84(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),3.95(t,J=10.3Hz,1H),2.84(dt,J=10.5,2 .3Hz,1H),2.75–2.67(m,1H),2.37(t,J=5.5Hz,2H),2.23(dd,J=14.5,6.7Hz,1H),2.18– 2.13(m,1H),2.01(s,1H),1.73(d,J=2.6Hz,3H),1.53(s,3H),1.49–1.42(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.30,165.71,143.12,139.37,138.52,138.30,132.82,129.22,128.61,121.54,119. 96,118.39,113.79,83.62,80.43,74.44,58.21,42.61,38.06,30.89,30.73,22.83,22.72ppm.HRMS(ESI)m / z calcd for C 25 H 25 NO5Na + [M+Na] + :442.1625;Found:442.1626.

[0091] The synthesis of compound 20-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain a white solid 20-b (38 mg, 76%). =-2.21 (c = 0.33, CHCl3). 1H NMR (400MHz, CDCl3) δ7.70–7.62(m,5H),6.53(d,J=16.0Hz,1H),6.24(d,J=3.4Hz,1H ),5.59(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.93(dd,J=11.0,10.0Hz,1H),3 .23(d,J=12.3Hz,1H),2.99(dt,J=11.2,2.7Hz,1H),2.49–2.42(m,2H),2.27(d,J=9.2 Hz,1H),1.93–1.84(m,2H),1.82–1.80(m,3H),1.74–1.68(m,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.55,165.43,142.67,140.92,138.54,138.44,132.65,131.16,128.45,121.60,119. 79,118.30,113.53,83.81,79.71,74.59,59.08,49.59,46.06,35.50,25.30,24.71,24.25ppm.HRMS(ESI)m / z calcd for C 25 H 25 NO5Na + [M+Na] + :442.1625;Found:442.1626.

[0092] 21. Synthesis of Compounds 21-a and 21-b

[0093] The synthesis of compound 21-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 21-a (33 mg, 76%). = +12.4 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.60(d,J=15.9Hz,1H),6.67(d,J=2.3Hz,2H),6.50(t,J=2.2Hz,1H),6.40(d,J =15.9Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.9,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.96–3.89(m ,1H),3.81(s,6H),3.27(ddd,J=14.1,9.4,2.6Hz,1H),3.01(dt,J=10.8,2.8Hz,1H),2.48–2.41(m,2H ),2.27(q,J=8.7,6.0Hz,1H),1.97–1.82(m,2H),1.81(s,3H),1.72–1.66(m,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.45,166.44,161.16,145.67,138.99,138.36,136.09,129.48,120.00,118.33,106.07 ,103.13,83.75,80.44,73.88,58.14,55.61,42.60,38.06,30.86,30.77,22.85,22.73ppm.HRMS(ESI)m / zcalcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1886.

[0094] The synthesis of compound 21-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain a white solid 21-b (21 mg, 65%). =-1.65 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.59(d,J=15.9Hz,1H),6.66(d,J=2.3Hz,2H),6.49(t,J=2.2Hz,1H),6.37(d,J=15.9 Hz,1H),6.25(d,J=3.3Hz,1H),5.83(d,J=6.6Hz,1H),5.54(d,J=3.1Hz,1H),4.01–3.94(m,1H),3.81(s,6H ),2.84(d,J=10.7Hz,1H),2.74–2.67(m,1H),2.36(d,J=6.6Hz,2H),2.22(dd,J=14.3,6.8Hz,1H),2.15(dd ,J=13.9,2.3Hz,1H),2.00(d,J=14.4Hz,1H),1.74(d,J=2.6Hz,3H),1.54(s,3H),1.50–1.42(m,1H)ppm.13C NMR (100MHz, CDCl3) δ169.76,166.33,161.16,145.31,140.79,138.63,136.24,131.47,119.90,118.59,106 .14,102.81,84.03,79.91,74.27,59.25,55.60,49.74,46.18,35.63,25.45,24.85,24.39ppm.HRMS(ESI)m / z calcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1885.

[0095] 22. Synthesis of Compounds 22-a and 22-b

[0096] The synthesis of compound 22-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 22-a (29 mg, 91%). = +24.3 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.98(d,J=16.1Hz,1H),7.04(d,J=0.3Hz,1H),6.92(dd,J=9.0,3.0Hz,1H),6.85(d,J=9.0 Hz,1H),6.23(d,J=3.4Hz,1H),5.58(dd,J=4.8,2.1Hz,1H),5.50(d,J=3.1Hz,1H),3.96–3.89(m,1H),3.85(s,3 H),3.79(s,3H),3.28(ddt,J=12.1,9.9,2.8Hz,1H),3.02(dt,J=11.1,2.8Hz,1H),2.50–2.45(m,1H),2.45–2.4 1(m,1H),2.27(dd,J=14.3,6.8Hz,1H),1.96–1.82(m,2H),1.81(s,3H),1.71–1.64(m,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.52,167.00,153.61,153.04,141.01,138.80,138.43,129.63,123.66,119.97,118.44,117.80 ,113.35,112.54,83.84,80.44,73.65,58.12,56.21,55.95,42.60,38.07,30.85,30.79,22.86,22.73ppm.HRMS(ESI)m / z calcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1886.

[0097] The synthesis of compound 22-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain a white solid 22-b (26 mg, 70%). =-55.4 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.98(d,J=16.1Hz,1H),7.04(d,J=0.3Hz,1H),6.91(dd,J=9.0,3.0Hz,1H),6.85(d,J=9.0Hz,1H) ,6.44(d,J=16.1Hz,1H),6.25(d,J=3.3Hz,1H),5.84(d,J=6.5Hz,1H),5.54(d,J=0.3Hz,1H),4.01–3.95(m,1H),3.84( s,3H),3.79(s,3H),2.84(d,J=10.7Hz,1H),2.74–2.67(m,1H),2.36(d,J=6.2Hz,2H),2.22(dd,J=14.4,6.6Hz,1H),2. 17–2.12(m,1H),2.00(d,J=14.3Hz,1H),1.74(d,J=2.6Hz,3H),1.55(s,3H),1.48(ddd,J=11.1,4.1,1.9Hz,1H)ppm.13C NMR (100MHz, CDCl3) δ169.81,166.80,153.62,152.96,140.65,140.48,138.68,131.57,123.92,119.86,118.66,117.40,11 3.36,112.60,84.07,79.96,74.01,59.27,56.28,55.95,49.78,46.22,35.62,25.45,24.81,24.40ppm.HRMS(ESI)m / zcalcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1887.

[0098] 23. Synthesis of Compounds 23-a and 23-b

[0099] The synthesis of compound 23-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 23-a (28 mg, 73%). = +19.83 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.62(d,J=16.1Hz,1H),7.11(d,J=8.2Hz,1H),7.06(s,1H),6.87(d,J= 8.9Hz,1H),6.30(d,J=15.8Hz,1H),6.23(s,1H),5.58(s,1H),5.50(s,1H),3.92(s,7H),3.28 (t,J=11.2Hz,1H),3.02(d,J=10.8Hz,1H),2.64(s,1H),2.45(dd,J=18.4,6.9Hz,2H),2.26(d ,J=10.8Hz,1H),1.90(d,J=10.5Hz,1H),1.81(s,3H),1.72–1.65(m,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.49,166.78,151.43,149.34,145.57,138.81,138.40,129.63,127.20,123.12,119.97,115.42 ,111.07,109.45,83.79,80.45,73.62,58.12,56.11,56.04,42.62,38.06,30.85,30.75,22.85,22.72ppm.HRMS(ESI)m / z calcd forC 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1884.

[0100] The synthesis of compound 23-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 23-b (24 mg, 63%). =-2.50 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.61(d,J=16.1Hz,1H),7.10(d,J=8.3Hz,1H),7.04(s,1H),6.86(d,J=8.2 Hz,1H),6.27(d,J=14.2Hz,2H),5.83(d,J=6.3Hz,1H),5.54(s,1H),3.98(t,J=10.2Hz,1H),3.92 (s,6H),2.84(d,J=10.7Hz,1H),2.71(t,J=11.0Hz,1H),2.37(s,2H),2.22(dd,J=14.6,6.7Hz,1H ),2.15(d,J=14.0Hz,1H),2.00(d,J=14.4Hz,1H),1.74(s,3H),1.55(s,3H),1.46(s,1H)ppm.13C NMR (100MHz, CDCl3) δ169.74,149.39,145.23,140.64,138.69,131.65,127.40,123.00,119.84,115.74,111.16,109.68,8 4.07,79.94,74.08,59.30,56.13,56.07,49.79,46.26,35.65,30.19,29.85,25.50,24.88,24.37ppm.HRMS(ESI)m / zcalcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1885.

[0101] 24. Synthesis of Compounds 24-a and 24-b

[0102] The synthesis of compound 24-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 24-a (28 mg, 73%). = +17.62 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ8.03 (dd, J=16.1, 2.3Hz, 1H), 7.16 (d, J=7.9Hz, 1H), 7.06 (td, J=8.1, 2.2Hz, 1H) ,6.95(d,J=8.1Hz,1H),6.47(dd,J=16.2,2.3Hz,1H),6.23(t,J=2.8Hz,1H),5.58–5.58(m,2H),3.94( dd,J=10.4,2.2Hz,1H),3.87(s,6H),3.27(t,J=11.3Hz,1H),3.04–2.96(m,1H),2.63(d,J=2.3Hz,1H) ,2.51–2.39(m,2H),2.26(q,J=15.7,12.8Hz,1H),δ1.89(dd,J=25.6,14.9Hz,1H),1.81(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.47,166.77,153.26,148.65,140.48,138.89,138.41,129.58,128.41,124.35,119.97,119.26 ,118.94,114.32,83.81,80.42,73.79,61.54,58.17,56.01,42.61,38.07,30.85,30.81,22.85,22.72ppm.HRMS(ESI)m / z calcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1885.

[0103] The synthesis of compound 24-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain a white solid 24-b (23 mg, 63%). =-1.07 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ8.01(d,J=16.2Hz,1H),7.15(d,J=7.9Hz,1H),7.05(t,J=8.1Hz,1H),6.94(d,J=8.1Hz ,1H),6.44(d,J=16.1Hz,1H),6.26(s,1H),5.85(d,J=6.5Hz,1H),5.55(s,1H),3.98(t,J=10.3Hz,1H),3.85 0-04.01(m,6H),2.84(d,J=10.6Hz,1H),2.71(s,1H),2.50(s,1H),2.37(s,1H),2.22(dd,J=14.3,6.7Hz,1H ),2.15(d,J=13.6Hz,1H),2.00(d,J=14.3Hz,1H),1.74(s,3H),1.55(s,3H),1.46(d,J=23.5Hz,1H)ppm.13C NMR (100MHz, CDCl3) δ169.58,166.41,159.85,153.16,148.44,140.59,139.78,138.53,131.38,124.22,119.74,119.19 ,119.02,114.05,83.93,79.83,73.95,61.38,59.15,55.89,49.66,46.09,35.50,25.30,24.64,24.26ppm.HRMS(ESI)m / z calcd for C 26 H 30 O7 + [M+Na] + :447.1884;Found:447.1885.

[0104] 25. Synthesis of Compounds 25-a and 25-b

[0105] The synthesis of compound 25-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=8 / 1) to obtain a white solid 21a (28 mg, 56%). = +18.30 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.90 (dd, J=16.2, 2.0Hz, 1H), 7.28 (d, J=2.1Hz, 1H), 6.69 (dd, J=8.8, 2.0Hz, 1H), 6.40(dd,J=16.1,2.0Hz,1H),6.23(t,J=2.5Hz,1H),5.60–5.54(m,1H),5.50(t,J=2.5Hz,1H),3.97–3.8 4(m,9H),3.27(t,J=11.1Hz,1H),3.00(d,J=10.3Hz,1H),2.63(s,1H),2.50–2.39(m,2H),2.26(d,J=11. 4Hz,1H),1.90(q,J=10.3,9.1Hz,1H),1.81(s,3H),1.73–1.62(m,1H),1.34(s,3H),1.27(s,1H)ppm.13C NMR (100MHz, CDCl3) δ169.49,167.11,155.93,153.53,142.47,140.73,138.75,138.50,129.72,123.43,121.32,119.89,11 6.52,107.72,83.85,80.44,73.59,61.62,61.03,58.19,56.21,42.66,38.12,34.81,30.84,27.06,22.71ppm.HRMS(ESI)m / z calcd for C 27 H 32 8Na + [M+Na] + :507.1989;Found:507.1987.

[0106] The synthesis of compound 25-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 25-b (30 mg, 64%). =-1.67 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.88 (d, J = 16.1Hz, 1H), 7.27 (s, 1), 6.68 (d, J = 8.8Hz, 1H), 6.36 (dd, J = 15. 9,2.2Hz,1H),6.25(t,J=2.9Hz,1H),5.83(d,J=6.5Hz,1H),5.54(d,J=2.8Hz,1H),3.97(t,J=10. 7Hz,1H),3.95–3.84(m,9),2.83(d,J=10.7Hz,1H),2.70(t,J=11.4Hz,1H),2.50(s,1H),2.35(d ,J=7.4Hz,2H),2.26–2.11(m,2H),1.99(dd,J=14.3,2.2Hz,1H),1.74(s,3),1.27(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.77,166.88,155.79,153.43,142.52,140.57,140.09,138.71,131.65,123.21,121.50,119.81,11 6.92,107.76,84.08,79.97,73.89,61.60,61.05,59.30,56.21,49.81,46.27,35.64,31.38,27.06,24.36ppm.HRMS(ESI)m / z calcd for C 27 H 32 8Na + [M+Na] + :507.1989;Found:507.1985.

[0107] 26. Synthesis of Compounds 26-a and 26-b

[0108] The synthesis of compound 26-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=8 / 1) to obtain a white solid 26-a (27 mg, 53%). = +21.9 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.58 (dd, J=15.9, 2.2Hz, 1H), 6.76 (d, J=2.2Hz, 2H), 6.33 (dd, J=15.9, 2.2Hz, 1H), 6.24(d,J=2.9Hz,1H),5.61–5.53(m,1H),5.50(d,J=2.7Hz,1H),3.94(d,J=10.9Hz,1H),3.89(dd,J=5.0, 2.1Hz,9H),3.28(t,J=10.9Hz,1H),3.03(d,J=10.9Hz,1H),2.63(s,1H),2.45(dd,J=18.5,7.1Hz,2H),2. 27(d,J=11.6Hz,1H),1.94–1.84(m,1H),1.81(s,3H),1.69(dd,J=14.4,11.9Hz,1H),1.34(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.43,166.49,153.62,145.60,140.48,138.98,138.44,129.74,129.60,119.90,117.09 ,105.44,83.76,80.48,73.83,61.14,58.16,56.34,42.69,38.12,34.81,30.87,27.06,22.72ppm.HRMS(ESI)m / z calcd for C 27 H 32 8Na + [M+Na] + :507.1989;Found:507.1988.

[0109] The synthesis of compound 26-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=6 / 1) to obtain a white solid 26-b (29 mg, 66%). =-2.43 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.58 (dd, J=15.9, 2.1Hz, 1H), 6.74 (d, J=2.1Hz, 2H), 6.38–6.21 (m, 2H), 5.8 3(d,J=6.5Hz,1H),5.54(t,J=2.6Hz,1H),3.97(t,J=10.4Hz,1H),3.88(s,9H),2.84(d,J=10.8Hz, 1H),2.71(t,J=11.1Hz,1H),2.52(s,1H),2.36(d,J=7.1Hz,2H),2.22(dd,J=14.5,6.7Hz,1H),2. 15(d,J=13.8Hz,1H),2.00(d,J=14.4Hz,1H),1.74(t,J=2.3Hz,3H),1.27(d,J=2.0Hz,3H)ppm.13C NMR (100MHz, CDCl3) δ169.70,166.39,153.58,145.29,140.73,140.40,138.63,131.56,129.88,119.85,117.28 ,105.44,84.02,79.89,74.24,61.12,59.27,56.32,49.75,46.23,35.63,31.37,27.04,24.36ppm.HRMS(ESI)m / z calcdfor C 27 H 32 8Na + [M+Na] + :507.1989;Found:507.1984.

[0110] 27. Synthesis of Compounds 27-a and 27-b

[0111] The synthesis of compound 27-a was the same as that of 3-a. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=5 / 1) to obtain a white solid 27-a (29 mg, 71%). = +23.6 (c = 0.3, CHCl3). 1H NMR (400MHz, CDCl3) δ7.59(d,J=15.9Hz,1H),7.04–7.01(m,2H),6.82(d,J=8.0Hz,1H),6.26(d,J=15.9Hz,1 H),6.23(d,J=3.4Hz,1H),6.01(s,2H),5.58–5.56(m,1H),5.50(d,J=3.1Hz,1H),3.96–3.90(m,1H),3.29–3 .22(m,1H),3.00(dt,J=11.0,2.8Hz,1H),2.64(s,1H),2.50–2.45(m,1H),2.43(dd,J=7.6,2.3Hz,1H),2.30 –2.21(m,1H),1.97–1.81(m,2H),1.80(s,3H),1.72–1.65(m,1H),1.57(d,J=9.2Hz,1H),1.33(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.49,166.77,149.99,148.54,145.36,138.85,138.37,129.52,128.69,124.87,120.02,11 5.72,108.72,106.60,101.77,83.81,80.42,73.72,58.16,42.57,38.04,30.86,30.83,22.85,22.73.HRMS(ESI)m / z calcd for C 26 H 28 O6Na + [M+Na] + :459.1778;Found:459.1777.

[0112] The synthesis of compound 27-b was the same as that of 3-b. The crude product was purified by silica gel column chromatography (200-300 mesh, mobile phase PE / EA=4 / 1) to obtain a white solid 27-b (27 mg, 67%). =-2.16 (c = 0.3, CHCl3). 1H NMR(400MHz, CDCl3) δ7.58(d,J=15.9Hz,1H),7.06–6.97(m,2H),6.81(d,J=8.0Hz,1H),6.32–6.17(m, 2H),6.01(s,2H),5.82(d,J=6.5Hz,1H),5.54(d,J=3.1Hz,1H),4.02–3.91(m,1H),2.83(d,J=10.8Hz, 1H),2.68–2.74(m,1H),2.50(s,1H),2.36(t,J=5.6Hz,2H),2.24–2.19(m,1H),2.13–2.17(m,1H),1.9 9(d,J=14.4Hz,1H),1.73(d,J=2.6Hz,3H),1.54–1.39(m,1H),1.36–1.26(m,1H),1.25(s,3H)ppm.13C NMR (100MHz, CDCl3) δ169.79,166.61,149.85,148.50,144.97,140.66,138.63,131.52,128.81,124.74,119.89,115. 98,108.69,106.59,101.74,84.05,79.92,74.06,59.23,49.74,46.17,35.61,29.84,25.43,24.83ppm.HRMS(ESI)m / z calcd for C 26 H 28 O6Na + [M+Na] + :459.1778;Found:459.1779.

[0113] 2. Biological Activity Test

[0114] 1. Test methods

[0115] PANC-1 cells were cultured in DMEM in a cell culture incubator at 37°C with 5% CO2. Cells were revived and passaged as usual: cryovials were taken out of liquid nitrogen, the cryovials were thawed in a 37°C water bath, centrifuged at 1000 rpm / min for 5 min, the supernatant was discarded, the cells were resuspended in complete culture medium, and cultured at 37°C with 5% CO2.

[0116] When the cells cover 70-80% of the bottom of the culture dish, discard the culture medium, wash with 2-3mL of PBS buffer, add 1-2mL of 0.25% trypsin (enough to cover the bottom of the bottle) for digestion, place in the incubator for a period of time until the cells become round, immediately add complete medium to stop digestion, combine the digested cell suspension, centrifuge at 1000rpm / min for 5min, discard the supernatant, resuspend the cells with complete medium, gently blow off the cells, inoculate them into a new culture dish according to a certain ratio, and place them in the incubator for culture. Take the cells in the logarithmic growth period, digest, centrifuge and count, adjust the volume to 1500-3500 cells / well, 95μL per well, and inoculate them into a 96-well plate.

[0117] After continuing to culture overnight, add drugs. Each group has 6 replicate wells, and 10 μL of drugs is added to each well. After incubation for 72 hours, add 10 μL of CCK-8 solution to each well (be careful not to generate bubbles in the wells, as they will affect the OD value reading). Incubate in the incubator for 1-4 hours, and measure the OD value at 450 nm with an enzyme reader to calculate the IC 50 The effect of each drug on each cell line was repeated three times. The data were processed by EXCEL software to solve the inhibition rate at different concentrations, and SPSS was used to fit the IC 50 EXCEL solves the IC 50 Value mean and standard deviation.

[0118] Inhibition rate % = {1-(OD value of drug well-OD value of blank well) / (OD value of control well-OD value of blank well)}*100%.

[0119] 2. Activity test

[0120] (1) Compounds 3-a and 3-b were used as controls and combined with cinnamic acid units carrying a single group on the benzene ring. According to the different substituents, the cinnamic acid units can be divided into two categories: electron-withdrawing groups (nitro, halogen, cyano, etc.) and electron-donating groups (hydroxyl, alkyl, alkoxy, etc.). A series of benzene ring monosubstituted cinnamic lactone-cinnamic acid derivatives 4-a to 20-a and 4-b to 20-b were synthesized. MCL was used as the basic raw material, and 9-hydroxy-substituted cinnamic lactone 2-a and 2-hydroxy-substituted cinnamic lactone 2-b were generated by Riley oxidation. Compounds 2-a and 2-b were esterified with various monosubstituted cinnamic acids to obtain compounds 4-a to 20-a and 4-b to 20-b, with yields of 65% to 92% and 58% to 87%. Et3N, DMAP and EDCI were used as condensing agents in the esterification reaction.

[0121] Depend on Fig.63 and Fig.64As can be seen, the activity results show that the introduction of strong electron-withdrawing groups and electron-donating groups will have a favorable effect on the improvement of the activity of the derivatives. Among them, the 4-CN substituted cinnamic acid derivative 20-a has an inhibition rate of 97.49% at a concentration of 10μ, and the IC50 value is as low as 3.731±1.065μM, showing the best anti-tumor activity.

[0122] (2) Using the same method, compounds 2-a and 2-b were esterified with multi-substituted cinnamic acid units (dimethoxy, trimethoxy, dihalogen, dialkyl substitution, etc.) at different substitution positions to obtain compounds 21-a~27-a and 21-b~27-b, with yields of 53%~76% and 63%~70%.

[0123] Depend on Fig.63 and 64 As shown, the trisubstituted methoxycinnamic acid-Michelia lactone derivative 26-a had an inhibition rate of 100.38% at a concentration of 10 μM, showing the best antitumor activity with an IC50 value of 3.731±1.065 μM. This indicates that as the number of electron-donating groups introduced into the cinnamic acid unit increases, the in vitro antitumor activity of Michelia lactone can be more favorably affected.

[0124] (3) Comparison of the in vitro activity data of disubstituted Michelolactones 21-a to 24-a and 21-b to 24-b and trisubstituted Michelolactones 25-a to 26-a and 25-b to 26-b, respectively.

[0125] Depend on Fig.63 and 64 As shown, the inhibition rate of 21-a at a concentration of 10μ reached 94.43, and the IC50 value was 7.146±2.055μM, and the inhibition rate of 26-a at a concentration of 10μ reached 100.38, and the IC50 value was 3.927±0.402μM. It can be seen that the higher the molecular symmetry, the higher the in vitro antitumor activity.

[0126] (4) Compounds 2-a and 2-b were condensed with heterocyclic 1,3-dihydroisobenzofuran and cinnamic acid units of pyridine ring to obtain compounds 27-a and 27-b. The yields were 71% and 67%. The IC50 values ​​of heterocyclic 1,3-dihydroisobenzofuran cinnamic acid unit compounds 27-a and 27-b were 18.721±1.031μM and 16.362±1.015μM, respectively. It can be seen that the overall activity of the 9-position cinnamic acid derivative containing cinnamic acid is better than that of the 2-position cinnamic acid derivative containing cinnamic acid.

[0127] 3. Test results

[0128] Depend on Fig.63 and Fig.64As can be seen, the activity results show that compounds 3-a to 27-a and 3-b to 27-b are effective in anti-tumor performance, and the activities of compounds 3-a to 9-a, 11-a to 16-a, 18-a, 20-a to 24-a, 26-a, 27-a, 4-b, 12-b to 14-b, 21-b, 23-b, 26-b, and 27-b are better than or equivalent to MCL. Among them, compounds 20-a and 26-a may be used as prodrugs of Michelia lactone, with the best anti-tumor performance, and can become potential new anti-tumor drugs.

[0129] Meanwhile, the pharmaceutical composition prepared by the present invention contains Michelia lactone-cinnamic acid derivatives and pharmaceutically acceptable pharmaceutical carriers, excipients or other tumor treatment drugs. The pharmaceutical carriers or excipients are one or more solid, semisolid, liquid preparations and pharmaceutical product adjuvants. The pharmaceutical composition is administered in two forms: injection or oral administration. The injection is intravenous injection or intramuscular injection, and the oral dosage form is tablets or capsules.

[0130] The present invention optimizes the structure of Michelia lactone and molecularly splices it with cinnamic acid units to synthesize a series of Michelia lactone-cinnamic acid derivatives, and the anti-tumor activity thereof is significantly improved through in vitro activity tests, thereby effectively improving the anti-tumor activity thereof, which is more conducive to clinical application.

[0131] The above description is only a preferred embodiment of the present invention and does not constitute any form of limitation to the invention. Any simple modification, equivalent change and modification made to the above embodiment in accordance with the technical essence of the present invention in order to deviate from the technical solution of the present invention shall fall within the scope of the technical solution of the present invention.

Claims

1. A Michelia lactone-cinnamic acid derivative, characterized in that: According to the different allylic oxidation sites of Michelia lactone, its general structural formula is shown in two structures: Formula Ⅰ and Formula Ⅱ: Among them, formula I is prepared from 9R-hydroxy Michelia lactone, and formula II is prepared from 9R-hydroxy Michelia lactone.

2. A Michelia lactone-cinnamic acid derivative according to claim 1, characterized in that: According to the different structures of cinnamic acid, R is represented differently, and R is one of the following structures: R=H, R=4-Br, R=2-OCH3, R=4-OCH3, R=2-CH3, R=2-OCF3, R=3-F, R=4-OH, R=4-F, R=2-OCH2CH3, R=4-CF3, R=4-Cl, R=2-OCOCH3, R=3-OCN3, R=3-Cl, R=4-isopropyl, R=4-OCH2CH3, R=4-CN, R=3,5-OCH3, R=2,5-OCH3, R=2,3-OCH3, R=3,4-OCH3, R=2,3,4-OCH3, R=3,4,5-OCH3, R=2,3,4-OCH3, R=3,4-dihydrofuran, R=3,4-pyridine.

3. A Michelia lactone-cinnamic acid derivative according to claim 2, characterized in that: The formula I is preferably The formula II is preferably 4. A pharmaceutical composition, characterized in that: The invention comprises the Michelia lactone-cinnamic acid derivative according to claim 1 and a pharmaceutically acceptable pharmaceutical carrier, excipient or other tumor treating drug.

5. The pharmaceutical composition according to claim 4, characterized in that: The pharmaceutical carrier or excipient is one or more solid, semisolid, liquid preparations and pharmaceutical product adjuvants. The pharmaceutical composition is administered in two forms: injection or oral administration. The injection is through intravenous injection or intramuscular injection, and the oral dosage form is tablets or capsules.

6. The use of the combined medicine according to claim 5, characterized in that: Used in drugs for treating various cancers.

7. A method for preparing a Michelia lactone-cinnamic acid derivative, characterized in that: The synthetic route is as follows: S1. Obtaining hydroxylated derivatives of Michelia lactone 9R-hydroxy Michelia lactone and 2R-hydroxy Michelia lactone by Riley oxidation; S2. The two hydroxy derivatives of Michelia lactone prepared in step S1 are molecularly spliced ​​with cinnamic acid units with different structures to synthesize a series of Michelia lactone-cinnamic acid derivatives (3-a) to (27-a) and (3-b) to (27-b).

8. The method for preparing a Michelia lactone-cinnamic acid derivative according to claim 7, characterized in that: The step S1 specifically includes the following steps: S11, at room temperature, add MCL into a dry three-necked round-bottom flask, then add dry DCM and dissolve it, then add SeO2 and t-BuOOH dried over anhydrous sodium sulfate, stir the mixture at room temperature for 6 hours, and set aside; S12. After most of the substrates are converted completely by TLC, a saturated Na2S2O3 solution is added to quench the reaction until a brick-red amorphous selenium precipitate appears in the reaction solution. The reaction solution is then filtered through diatomaceous earth and extracted with DCM. After the extraction is completed, the crude product is washed, dried, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product is purified by a silica gel column for later use. S13, adding the crude product purified in step S12 into a round-bottom flask, then adding dried DCM to dissolve it, then slowly adding dried Et3N to react, stirring the reaction solution for 15 minutes, adding TESCl, stirring the mixture reaction solution overnight, and adding H2O to quench the reaction after monitoring the complete conversion of the substrate by TLC, then extracting, washing, drying, filtering and concentrating under reduced pressure, and then purifying by silica gel column to obtain colorless oily compound 1-a and light yellow oily compound 1-b respectively; S14, dissolving the compound 1-a obtained in step S13 in a mixed solution of THF and TBAF, and stirring at room temperature overnight. After the TLC monitoring substrate is basically converted, H2O is added to quench the reaction, extracted with EtOAc, washed, dried, filtered, concentrated under reduced pressure, and purified with a silica gel column to obtain a yellow solid compound 2-a; dissolving the compound 1-b obtained in step S13 in a mixed solution of THF and TBAF, and stirring at room temperature overnight. After the TLC monitoring substrate is basically converted, H2O is added to quench the reaction, extracted with EtOAc, washed, dried, filtered, concentrated under reduced pressure, and purified with a silica gel column to obtain a yellow solid compound 2-a.

9. The method for preparing a Michelia lactone-cinnamic acid derivative according to claim 8, characterized in that: The step S2 specifically includes the following steps: At 0°C, compound 2-a prepared in step S14 is added to a round-bottom flask, DCM is added to dissolve it, and then Et3N and DMAP are added until the pH value of the solution is 9-10, and then cinnamic acid and EDCI are added, and the mixture is stirred overnight. After the substrate is basically converted as monitored by TLC, a saturated NaHCO3 solution is added to quench the reaction, and then extracted with DCM, washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered and concentrated under reduced pressure. It is then purified by silica gel chromatography to obtain the corresponding (3-a) to (27-a) cinnamic acid derivatives according to the different structures of the added cinnamic acid; At 0°C, compound 2-b prepared in step S14 is added to a round-bottom flask, DCM is added to dissolve it, and then Et3N and DMAP are added until the pH value of the solution is 9-10, and then cinnamic acid and EDCI are added, and the mixture is stirred overnight. After the substrate is basically converted completely as monitored by TLC, a saturated NaHCO3 solution is added to quench the reaction, and then extracted with DCM, washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered and concentrated under reduced pressure. Subsequently, it is purified by silica gel chromatography, and the corresponding (3-b) to (27-b) cinnamic acid derivatives are obtained according to the different structures of the added cinnamic acid.

10. The method for preparing a Michelia lactone-cinnamic acid derivative according to claim 8, characterized in that: In the step S11, the parameters of chalactone are 10.0 g, 40.21 mmol, 1.0 equiv, the parameters of SeO2 are 2.2 g, 20.14 mmol, 0.5 equiv, and the parameters of t-BuOOH are 13.0 g, 100.68 mmol, 2.5 equiv, 70% in H2O; in the step S13, the mixture is 5.0 g, 18.92 mmol, 1.0 equiv., the parameters of Et3N are 5.7 g, 56.75 mmol, 3.0 equiv.; the parameters of TESCl are 6.2 g, 56.75 mmol, 3.0 equiv.; in the step S14, the compound 2-a (20 mg, 75.67 mmol, 1 equiv.) is 2 g, 5.28 mmol, 1 equiv., and the parameters of the THF / TBAF mixed solution are 1.0 M TBAF in THF, 7.92 mmol, 7.92 mL; compound 1-b is calculated as 2 g, 5.28 mmol, 1 equiv., and the parameters of the THF / TBAF mixed solution are 1.0 M TBAF in THF, 7.92 mmol, 7.92 mL.